Avanos Medical (NYSE:AVNS) Lowered to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Avanos Medical from a "buy" to a "hold," and the stock's consensus rating on MarketBeat is "Reduce" after mixed analyst calls (one Hold, one Sell; Weiss Ratings kept a "sell").
• Avanos beat quarterly expectations with $0.29 EPS vs. $0.24 expected and $180.9M revenue vs. $174.7M, but its FY2026 guidance of $0.90–$1.10 EPS is below sell-side expectations of $1.32.
• Institutional ownership is very high at 95.17%, with major funds sharply increasing positions—Northwestern Mutual added ~14.9M shares (worth ~$167M) in the latest quarter.

Avanos Medical (NYSE:AVNS - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Avanos Medical in a research note on Monday, December 22nd. Zacks Research raised shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Reduce".

Avanos Medical Stock Down 0.1%

Shares of NYSE AVNS opened at $24.64 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -15.59 and a beta of 1.05. The stock has a 50 day moving average price of $14.90 and a 200 day moving average price of $12.87. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $24.72.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.05. The firm had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.Avanos Medical's quarterly revenue was up .7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Sell-side analysts expect that Avanos Medical will post 1.32 earnings per share for the current year.

Hedge Funds Weigh In On Avanos Medical

A number of large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. increased its position in shares of Avanos Medical by 1,596,514.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company's stock worth $167,287,000 after purchasing an additional 14,895,480 shares in the last quarter. Armistice Capital LLC increased its position in shares of Avanos Medical by 28.0% during the fourth quarter. Armistice Capital LLC now owns 3,200,000 shares of the company's stock worth $35,936,000 after purchasing an additional 700,000 shares in the last quarter. Millennium Management LLC increased its position in shares of Avanos Medical by 312.4% during the third quarter. Millennium Management LLC now owns 896,242 shares of the company's stock worth $10,361,000 after purchasing an additional 678,898 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Avanos Medical by 356.6% during the third quarter. Ameriprise Financial Inc. now owns 591,181 shares of the company's stock worth $6,834,000 after purchasing an additional 461,706 shares in the last quarter. Finally, Citadel Advisors LLC increased its position in shares of Avanos Medical by 212.0% during the third quarter. Citadel Advisors LLC now owns 574,104 shares of the company's stock worth $6,637,000 after purchasing an additional 390,082 shares in the last quarter. Institutional investors own 95.17% of the company's stock.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.